Literature DB >> 17457365

Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism.

Giuseppe Pignataro1, Samaneh Maysami, Francesca E Studer, Andrew Wilz, Roger P Simon, Detlev Boison.   

Abstract

The rate of ischemic brain injury varies with the brain region, requiring only hours in striatum but days in hippocampus. Such maturation implies the existence of endogenous neuroprotective mechanisms. Adenosine is an endogenous neuroprotectant regulated by adenosine kinase (ADK). To investigate, whether adenosine might play a role in protecting the hippocampus after focal ischemia, we subjected transgenic mice, which overexpress ADK in hippocampal neurons (Adk-tg mice) to transient middle cerebral artery occlusion (MCAO). Although the hippocampus of wild-type (wt) mice was consistently spared from injury after 60 mins of MCAO, hippocampal injury became evident in Adk-tg mice after only 15 mins of MCAO. To determine, whether downregulation of hippocampal ADK might qualify as candidate mechanism mediating endogenous neuroprotection, we evaluated ADK expression in wt mice after several periods of reperfusion after 15 or 60 mins of MCAO. After 60 mins of MCAO, hippocampal ADK was significantly reduced in both hemispheres after 1, 3, and 24 h of reperfusion. Reduction of ADK-immunoreactivity corresponded to a 2.2-fold increase in hippocampal adenosine at 3 h of reperfusion. Remarkably, a significant reduction of ADK immunoreactivity was also found in the ipsilateral (stroked) hippocampus after 15 mins of MCAO and 3 h of reperfusion. Thus, transient downregulation of hippocampal ADK after stroke might be a protective mechanism during maturation hippocampal cell loss.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457365     DOI: 10.1038/sj.jcbfm.9600499

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  43 in total

1.  Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy.

Authors:  Eleonora Aronica; Emanuele Zurolo; Anand Iyer; Marjolein de Groot; Jasper Anink; Caterina Carbonell; Erwin A van Vliet; Johannes C Baayen; Detlev Boison; Jan A Gorter
Journal:  Epilepsia       Date:  2011-06-02       Impact factor: 5.864

2.  Adenosine dysfunction and adenosine kinase in epileptogenesis.

Authors:  Detlev Boison
Journal:  Open Neurosci J       Date:  2010-01-01

3.  Chopping Out CHOP Chops the Fate of Neurons.

Authors:  Detlev Boison
Journal:  Epilepsy Curr       Date:  2013-09       Impact factor: 7.500

Review 4.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

Review 5.  The role of adenosine in epilepsy.

Authors:  Landen Weltha; Jesica Reemmer; Detlev Boison
Journal:  Brain Res Bull       Date:  2018-11-20       Impact factor: 4.077

6.  Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen.

Authors:  Rkia El-Kharrag; Randy Owen; Detlev Boison
Journal:  J Caffeine Adenosine Res       Date:  2019-03-14

Review 7.  Glial adenosine kinase--a neuropathological marker of the epileptic brain.

Authors:  Eleonora Aronica; Ursula S Sandau; Anand Iyer; Detlev Boison
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

8.  Inhibition of Adenosine Kinase Attenuates Acute Lung Injury.

Authors:  David Köhler; Ariane Streienberger; Julio C Morote-García; Tiago F Granja; Mariella Schneider; Andreas Straub; Detlev Boison; Peter Rosenberger
Journal:  Crit Care Med       Date:  2016-04       Impact factor: 7.598

9.  Adenosine neuromodulation and traumatic brain injury.

Authors:  T A Lusardi
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 10.  Adenosine signaling and function in glial cells.

Authors:  D Boison; J-F Chen; B B Fredholm
Journal:  Cell Death Differ       Date:  2009-09-18       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.